MoneyWorks4Me

Aurobindo Pharma informs about issuance of letter of confirmations

08 Dec 2023 Evaluate

Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of SEBI Circular No. SEBI / HO / MIRSD / MIRSD_RTAMB / P / CIR / 2022 / 8 dated January 25, 2022, Aurobindo Pharma has informed that the Company has approved the issuance of ‘Letter of Confirmations’ in lieu of duplicate share certificates, which were reported as lost by the shareholders: Subhas Kumar Patodia (Folio No: APL033412) & Aruna Ch (Folio No: APL027500), further details are enclosed. 

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1631.65 0.65 (0.04%)
28-Aug-2026 13:41 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1923.25
Dr. Reddys Labs. 1180.50
Cipla 1415.50
Lupin 2171.75
Zydus Lifesciences 1174.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: